Olivier Charmeil - Sanofi Insider

SNYNF -- USA Stock  

USD 80.15  0.000002  0.00%

Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team

Mr. Olivier Charmeil has served as Executive Vice President and General Manager, General Medicines Emerging Markets Member of the Executive Committee of Sanofi S.A. since June 2016. Prior to that, he was Executive Vice President Vaccines, Member of the Executive Committee and Global Leadership Team of the Company. He joined the Company as Senior Vice President Pharmaceutical Operations in AsiaPacific Region on February 1, 2006, the function he held until January 1, 2008, when he became appointed Senior Vice President Pharmaceutical Operations in Asia Pacific Region and Japan for over one year, until February 2009. From then to January 1, 2011, he served as Senior Vice President AsiaPacific Japan Vaccines, Member of the Management Committee of the Company. From 1989 to 1994, he worked in the Mergers and Acquisitions department of Banque de lUnion Europeenne. He joined Sanofi Pharma in 1994 as Head of Business Development. Subsequently, he held various posts within the Group, including Chief Financial Officer for SanofiSynthelabo in 1999 and Attache to the Chairman, JeanFrancois Dehecq, in 2000, before being appointed as Vice President of Development within the SanofiSynthelabo International Operations Division, where he was responsible for China and support functions. In 2003, Mr. Charmeil was appointed Chairman and Chief Executive Officer of SanofiSynthelabo France, before taking the post of Senior Vice President of Business Management and Support within the Pharmaceutical Operations Division. Mr. Charmeil obtained a degree from the Hautes etudes commerciales and from the Institut dEtudes Politiques de Paris.
Age: 53  President Since 2016      
33 1 53 77 40 00  http://www.sanofi.com

Management Efficiency

The company has return on total asset (ROA) of 4.5 % which means that it generated profit of $4.5 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 6.75 % meaning that it generated $6.75 on every $100 dollars invested by stockholders.
The company has accumulated 19.18 B in total debt with debt to equity ratio (D/E) of 26.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sanofi has Current Ratio of 1.68 which is within standard range for the sector.

Similar Executives

Entity Summary

It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1 and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi is traded on OTC Market in USA.Sanofi (SNYNF) is traded on OTC Market in USA. It is located in 54, Rue La Bo?tie and employs 106,566 people.

Sanofi Leadership Team

Dominique Carouge, President
Claudie Haignere, Director
Olivier Brandicourt, CEO
Pascale Witz, President, MBA
Serge Weinberg, Chairman
Suresh Kumar, President
Kathleen Tregoning, President
Sebastien Martel, President, MBA
William Sibold, President, MBA
Peter Guenter, President
Fabienne Lecorvaisier, Director
George Grofik, President
Karen Linehan, President
David Loew, President, MBA
Muzammil Mansuri, President, Ph.D
Klaus Pohle, Director
Diane Souza, Director
Bernard Charles, Director, Ph.D
Carole Piwnica, Director
Elias Zerhouni, President, Ph.D
Ameet Nathwani, President
Philippe Luscan, President
Roberto Pucci, President
DavidAlexandre Gros, President
Olivier Charmeil, President
Melanie Lee, Director, Ph.D
Igor Landau, Director
Patrick Kron, Director
Bonnie Bassler, Director
Thomas Suedhof, Director
Laurent Attal, Director
JeanRene Fourtou, Director
Gerard Kemmel, Director, MBA
SuetFern Lee, Director
Carsten Hellmann, President
David Meeker, President, Ph.D
Christian Mulliez, Director
Robert Castaigne, Director, Ph.D
Alan Main, President
Suet Lee, Director
Jerome Contamine, President
Uwe Bicker, Director, Ph.D

Stock Performance Indicators

Did you try this?

Run Portfolio Optimization Now
   

Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
All  Next Launch Portfolio Optimization

Trending Equities

Currently Active Assets on Macroaxis
OZL   
Purchased over 100 shares of
six days ago
Traded for 10.44
FBU   
Purchased over 300 shares of
six days ago
Traded for 6.24
JBH   
Purchased over 70 shares of
six days ago
Traded for 23.42
GNC   
Purchased over 200 shares of
six days ago
Traded for 8.1
SBM   
Purchased over 400 shares of
six days ago
Traded for 4.74
Also please take a look at World Market Map. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.